Clinical Trial Update: A Study of a Single Dose of ASP3291 in Subjects With Ulcerative Colitis [Phase 1]

View source ↗

Summary

Phase 1 trial assessing safety and tolerability of a single dose of ASP3291 in adults with Ulcerative Colitis; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• ASP3291

Snippet

Sponsor: Telsar Pharma Inc. | Conditions: Ulcerative Colitis | Phase 1 | Status: COMPLETED